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Letter to the Editor
Evidence of Serological Cross-Reactivity between Genotype 1 and Genotype 3
Erythrovirus Infections
Candotti and colleagues (1) reported the prevalence of a
third strain of human erythrovirus, genotype 3 (V9), in the
Ghanaian population and, in part, concluded that a genotype 1
(B19)-based assay failed to detect genotype 3 immunoglobulin
G (IgG) in 38.5% of Ghanaian samples containing genotype 3
antibodies. We disagree with this conclusion for the following
reasons. (i) No details are furnished as to the expression sys-
tem used for V9 VP1 production, the conformational status of
the protein (denatured or native structure), or the purity or the
concentration of the genotype 3 VP1 protein used for micro-
plate coating. (ii) The number of specimens used to establish
the cutoff of the V9 VP1 enzyme immunoassay (EIA) was
extremely small (n  4). (iii) The high degree of homology
among capsid proteins of genotypes 1 through 3 would suggest
that antibodies raised against one capsid type would be cross-
reactive with the others (3, 7).
With respect to the first point, it is interesting that all spec-
imens, seropositive in the genotype 1 VP2 EIA, were also
positive in the genotype 3 “in-house” VP1 EIA (1), thus con-
firming that the genotype 1 assay could actually detect anti-
bodies produced as a result of either genotype 1 or genotype 3
infection. This is supported by the fact that the seronegative
specimens (genotype 1 EIA) were also negative by the geno-
type 3 EIA. An apparent discrepancy occurred only with the
genotype 3 EIA, whereby certain specimens that were serore-
active via the genotype 3 EIA were negative when tested with
the genotype 1 EIA. The absence of critical experimental in-
formation regarding VP1 production, purification, and immu-
noassay procedures cast doubt over the conclusions drawn by
the authors with respect to genotype 3 immunoassay perfor-
mance. Many erythrovirus VP1 purification procedures involve
protein denaturation, thus destroying many of the diagnosti-
cally relevant conformational epitopes (5, 6, 8). It is well es-
tablished, in genotype 1 erythrovirus infections, that IgG di-
rected against linear epitopes of VP1 gradually declines
postinfection but is maintained against conformational
epitopes of VP1 and VP2 (4, 5, 6, 8). Therefore, if the VP1
used by Candotti and coworkers was denatured, then the assay
would detect only antibodies against linear epitopes and would
not identify all past erythrovirus infections. As the genotype 1
EIA used in this study utilizes capsid VP2, it can detect anti-
bodies against conformational epitopes, thereby conferring
high sensitivity of detection. Candotti and colleagues directly
compared an EIA which uses genotype 3 VP1 structural pro-
tein, of unclear pedigree, to one that has been extensively
validated (2) and employs genotype 1 VP2 structural protein.
The small panel of only four negative specimens used to
determine the cutoff may increase the risk of obtaining false
positives in the genotype 3 EIA. Indeed, it is notable that every
specimen that was reactive only in the genotype 3 EIA had a
significantly lower level of reactivity than those that were re-
active in both the genotype 1 and genotype 3 EIAs. Thus, to
verify these results, we suggest that an alternative method, such
as an immunoblot, should have been employed.
It is worthy to note also the high degree of homology of the
VP2 capsid proteins of genotypes 1 through 3, which would be
expected to result in a high level of immunological cross-
reactivity between these viruses (7). In fact, a previous study
showed that a genotype 1 VP2-specific IgM EIA was capable of
detecting both genotype 2 and genotype 3 viral infections (7).
In addition, a genotype 3 immune response was initially de-
tected by counterimmunoelectrophoresis with a genotype 1
virus-specific serum (7). Serological screening by enzyme-
linked immunosorbent assay using genotype 3 recombinant
VP2 found that the results were 100% concordant with those
obtained by an enzyme-linked immunosorbent assay which
uses genotype 1 VP2 as the antigen (3). This outcome indicates
significant serological cross-reactivity against the genotype 1
and genotype 3 VP2 protein, making it an excellent protein for
use as a diagnostic antigen. Conversely, as there is a greater
degree of variation in the VP1 unique region between the
three genotypes at the amino acid level, in particular, in one of
the major neutralization epitopes, the use of VP1 alone would
have been more appropriate to determine if there was a dif-
ferential genotype-specific antibody response.
It is important to acknowledge that in the DNA-negative
cohort from Ghana (1), the genotype 1-based assay was capa-
ble of detecting erythrovirus-specific IgG in 70% (107 of 153)
of those tested. This rate is the average seroprevalence rate for
the adult population (5, 9) and would imply that this assay was
capable of detecting all genotype 3 infections if genotype 3
erythrovirus is prevalent in Ghana.
Finally, it should be noted that the genotype 1 VP2-based
EIA is the only immunoassay capable of detecting erythrovirus
IgG to have been cleared by the U.S. Food and Drug Admin-
istration and, as such, has been subject to extensive public
validation (2). We submit that a more robust study is needed to
confirm whether antibodies against all three erythrovirus ge-
notypes cannot be detected using EIAs based on the capsid
VP2 protein of genotype 1. The information, as presented by
Candotti and coworkers, does not support this contention.
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Authors’ Reply
We are grateful to Drs. Corcoran and Doyle to extend the
discussion regarding the utility of VP2 genotype 1-based assays
to detect antibodies to human erythrovirus (HEV) genotype 3.
They question the origin of the genotype 3 antigen (V9) we
used and the specificity of our enzyme immunoassay and infer
that if antibodies from genotype 1-infected individuals react
well with genotype 3 VP2 protein, the reverse might be true. It
is unfortunate that the authors did not concede that the two
samples containing both genotype 3 viral DNA and specific
antibodies were not reactive with the Biotrin assay.
As to the pedigree of the V9 antigen, it was obtained from
Drs. K. Brown and E. D. Heegaard, who prepared it and
showed that genotype 1 antibodies cross-reacted with this an-
tigen (4). This antigen was purified capsids formed of both VP1
and VP2 proteins, presenting conformational as well as linear
epitopes (4). The discussion is limited to the efficacy of VP2
genotype 1 antigen to detect antibodies raised by genotype 3
HEV infection, a situation not assessed in a population prior to
our article (3). As we point out in the discussion, it is possible
that the VP1/VP2 V9 antigen contained epitopes not present
in genotype 1 VP2 (particularly, neutralizing) and that these
epitopes, eliciting antibodies with a different timing of occur-
rence than antibodies to VP2 capsids, might have given the
V9-based test a sensitivity advantage (3).
Using four negative controls to determine the cutoff of an
indirect EIA is not unusual, provided the cutoff was defined
with a greater number of negative samples. Since 100% con-
cordance between genotype 1- and genotype 3-based assays for
genotype 1 antibody detection was found, the specificity of
Heegaard’s assay was not contested for this type of antibodies.
It would be unlikely that false-positive reactivity would be
restricted to testing a genotype 3-infected population. The
likelihood that the assay was equally specific irrespective of the
prevalent genotype is fairly high.
The argument of expecting the antibody prevalence found in
adult populations from Western countries, such as France,
United Kingdom, the United States of America, and Denmark,
to be similar to that in West Africa does not stand, considering
the difference in the standards of hygiene between these geo-
graphical areas. It is well known that the prevalence of ubiq-
uitous viruses, such as cytomegalovirus, varicella-zoster virus,
and human herpesvirus 8 in sub-Saharan Africa is significantly
higher than that in Northern countries (1, 2). A higher preva-
lence of antibodies to HEV, as shown in other parts of Africa
(5) was therefore expected in Ghana.
Finally, we agree that more data and comparisons with as-
says differing from each other only by the genotype of the
capture antigen need to be collected. We are preparing puri-
fied recombinant antigens of VP2, VP1/VP2, and VP1 unique
regions of HEV genotypes 1 and 3. The genotype 3 antigens
were obtained from a Ghanaian strain. Direct comparisons of
EIAs on sera from areas where genotypes 1 and 3 are prevalent
will be conducted with large numbers of samples with all the
technical guarantees required by the Biotrin group.
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